Recent filings detail significant insider activity at Iradimed Corp (NASDAQ: IRMD), involving its Chief Executive Officer, President, and Chairman, Roger E. Susi. Through indirect means, Mr. Susi sold 7,500 shares of the company's common stock, amounting to a total value of $657,264. These divestitures were completed over two days, specifically on May 18 and May 19, 2026, with the selling price per share fluctuating between $85.95 and $88.65.
The sale was managed through the Phillip Susi 2008 Dynasty Trust, an entity that holds indirect beneficial ownership of Mr. Susi's shares. Crucially, these transactions were executed under the framework of a Rule 10b5-1 trading plan, which Mr. Susi had originally established on November 5, 2025.
The timing of these sales follows a period where IRMD stock experienced notable gains, delivering a strong 66% return over the course of the past year. Despite this positive performance, an analysis provided by InvestingPro suggested that the current valuation of the shares might exceed the company's calculated Fair Value.
Beyond the insider selling activity, Iradimed Corporation released its first-quarter 2026 earnings report, providing a snapshot of the company's recent financial health. The reported figures demonstrated an outperformance relative to market expectations.
Specifically, the company reported an earnings per share (EPS) of $0.49 for the quarter. This figure surpassed the analyst consensus forecast of $0.46, representing a surprise margin of 6.52%. Furthermore, the revenue figures also exceeded projections, reaching $22 million when analysts had anticipated $20.8 million.
Despite these positive financial results and beat expectations from the earnings report, the company's stock faced a decline during pre-market trading. These conflicting developments highlight both the strong underlying operational performance of the firm and subsequent market reactions that may be influenced by unspecified factors.
In terms of current share holdings associated with Mr. Susi, the Phillip Susi 2008 Dynasty Trust currently maintains a holding of 2,172,500 shares of IRADIMED CORP common stock. Additionally, Mr. Susi retains an indirect stake of 162,950 shares via the Roger E. Susi Revocable Trust. A further block of 2,062,500 shares is indirectly held by the Matthew Susi 2008 Dynasty Trust; however, it must be noted that Mr. Susi disclaims beneficial ownership of these particular securities, except to the limited extent defined by his pecuniary interest.
Risks
- Potential overvaluation of the stock relative to its intrinsic fair value, as suggested by analysis.
- Market uncertainty leading to a decline in pre-market trading immediately following strong earnings reports.
- The impact of unspecified factors causing market concern despite positive financial performance.
More from Insider Trading
Risks
- Potential overvaluation of the stock relative to its intrinsic fair value, as suggested by analysis.
- Market uncertainty leading to a decline in pre-market trading immediately following strong earnings reports.
- The impact of unspecified factors causing market concern despite positive financial performance.